CD8A and neoplasm: In metastatic breast cancer patients, treatment with daclizumab durably reduced circulating CD25highFOXP3+ Tregs favoring the population of tumor-specific cytotoxic CD8+T cells (CTLs) after vaccination with cancer antigen peptides (hTERT/survivin) [131].